BioNotebook: First trial for Bellicum's CAR T cell safety switch; deals, trials, financings
This article was originally published in Scrip
Executive Summary
NCI study uses Bellicum's CAR T cell safety switch; Innocutis licenses Sitavig from BioAlliance; Portola initiates andexanet alfa Phase III; Alcobra enrolls first Phase III patient; Cardium becomes Taxus Cardium; Sangamo prices $100m offering; Alexza completes $45m private placement; and Oxygen raising $52m.
You may also be interested in...
Rising Tide Lifts All CAR-T Ships After Gilead/Kite Deal, Kymriah Approval
Excitement around cell therapy has been building in recent years, but companies expect interest to accelerate after Gilead agreed to buy Kite for $11.9bn and Novartis won the first ever CAR-T approval.
Sage’s Dalzanemdor Prospects In Doubt After First Mid-Stage Readout
Dalzanemdor (SAGE-718) showed no difference from placebo in a Phase II Parkinson’s disease study, raising concerns about readouts later this year in Huntington’s and Alzheimer’s diseases.
First Phase III Depression Data For Intra-Cellular’s Caplyta Exceed Expectations
With positive results from the first Phase III trial of lumateperone in major depressive disorder and a second readout expected later this quarter, the company plans a supplemental filing in late 2024.